Characteristics and outcomes of clinical reports on allogeneic serum eye drop therapy
| Reference | Size | Pathology | Treatment | Result | Complications |
|---|---|---|---|---|---|
| Chiang et al25 | 36 eyes | PED | 100% allogeneic serum hourly (monotherapy) | 15 (42%) of PEDs healed within 2 weeks | None |
| Chiang et al30 | 2 patients | GVHD-related DES | 100% allogeneic serum hourly (monotherapy) | Patient 1: improved symptoms, TBUT and corneal staining at 2 weeks; Patient 2: improved symptoms, resolution of filamentous keratopathy at 1 week | None |
| Na and Kim17 | 16 patients | GVHD-related DES | 20% allogeneic serum 6–8 times/day (with PFAT) | Improved OSDI score, corneal staining, impression cytology grade and tear osmolarity at 4 weeks | None |
| Harritshøj et al51 | 20 DES patients, 14 PED eyes | PED and DES | 20% allogeneic serum (frequency not specified) | 80% (16) DES patients with improved symptoms and corneal staining, no subjective or objective effects on PED group at 4 weeks | None |
DES, dry eye syndrome; GVHD, graft-versus-host disease; OSDI, Ocular Surface Disease Index; PED, persistent epithelial defect; PFAT, preservative-free artificial tears; TBUT, tear break-up time.